WO2008055013A3 - 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de la kinase c-fms - Google Patents

5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de la kinase c-fms Download PDF

Info

Publication number
WO2008055013A3
WO2008055013A3 PCT/US2007/081930 US2007081930W WO2008055013A3 WO 2008055013 A3 WO2008055013 A3 WO 2008055013A3 US 2007081930 W US2007081930 W US 2007081930W WO 2008055013 A3 WO2008055013 A3 WO 2008055013A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
pyrido
pyrimidines
dihydro
oxo
Prior art date
Application number
PCT/US2007/081930
Other languages
English (en)
Other versions
WO2008055013A2 (fr
Inventor
Mark R Player
William H Parsons
Hui Huang
Daniel A Hutta
Huaping Hu
James Rinker
Original Assignee
Janssen Pharmaceutica Nv
Mark R Player
William H Parsons
Hui Huang
Daniel A Hutta
Huaping Hu
James Rinker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Mark R Player, William H Parsons, Hui Huang, Daniel A Hutta, Huaping Hu, James Rinker filed Critical Janssen Pharmaceutica Nv
Publication of WO2008055013A2 publication Critical patent/WO2008055013A2/fr
Publication of WO2008055013A3 publication Critical patent/WO2008055013A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

L'invention traite du besoin actuel en inhibiteurs sélectifs et puissants de protéine tyrosine kinase en proposant des inhibiteurs puissants de la kinase c-fms. L'invention porte sur les nouveaux composés représentés par la Formule I : ou un sel, un stéréoisomère, un tautomère, un dérivé cristallin, un dérivé polymorphe, un dérivé amorphe, un solvate, un hydrate, un ester, un promédicament ou une forme métabolite de celui-ci, et où A, Y, Z, R101 et R200 sont décrits dans la revendication.
PCT/US2007/081930 2006-10-31 2007-10-19 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de la kinase c-fms WO2008055013A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85552306P 2006-10-31 2006-10-31
US60/855,523 2006-10-31

Publications (2)

Publication Number Publication Date
WO2008055013A2 WO2008055013A2 (fr) 2008-05-08
WO2008055013A3 true WO2008055013A3 (fr) 2009-01-22

Family

ID=39144475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/081930 WO2008055013A2 (fr) 2006-10-31 2007-10-19 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de la kinase c-fms

Country Status (4)

Country Link
US (1) US20080114007A1 (fr)
AR (1) AR063723A1 (fr)
CL (1) CL2007003163A1 (fr)
WO (1) WO2008055013A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642270B2 (en) * 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
BRPI1015135B1 (pt) 2009-06-29 2021-08-03 Incyte Holdings Corporation Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos
WO2011075643A1 (fr) * 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
AR079529A1 (es) * 2009-12-18 2012-02-01 Incyte Corp Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
EP2558463A1 (fr) 2010-04-14 2013-02-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de i3
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012087881A1 (fr) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
US8518214B2 (en) 2011-07-18 2013-08-27 Nalco Company Debonder and softener compositions
ES2722524T3 (es) 2011-09-02 2019-08-13 Incyte Holdings Corp Heterociclaminas como inhibidores de pi3k
JP2014530867A (ja) 2011-10-20 2014-11-20 アッヴィ・インコーポレイテッド キナーゼのピリドピリミジノン阻害剤
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN104428282B (zh) 2012-07-12 2017-10-20 日产化学工业株式会社 肟取代酰胺化合物和有害生物防除剂
WO2015019037A1 (fr) * 2013-08-05 2015-02-12 Almac Discovery Limited Composés pharmaceutiques
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
MD3831833T2 (ro) 2015-02-27 2023-04-30 Incyte Holdings Corp Procedee pentru prepararea unui inhibitor PI3K
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
EP3877380A1 (fr) 2018-11-05 2021-09-15 Syngenta Participations Ag Composés azole-amide à action pesticide
WO2020191503A1 (fr) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Procédés et utilisations de bromantane et de dérivés de celui-ci pour le traitement d'une maladie pulmonaire, d'une stéatose hépatique et de troubles rénaux
CN112457309B (zh) * 2020-09-01 2023-03-17 扬州工业职业技术学院 一种苯基取代吡啶并嘧啶胺类化合物及其作为抗菌药物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09221424A (ja) * 1995-12-13 1997-08-26 Dainippon Pharmaceut Co Ltd 抗腫瘍剤
WO2001070741A1 (fr) * 2000-03-06 2001-09-27 Warner-Lambert Company Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido[2,3-d]pyrimidines
WO2007033232A1 (fr) * 2005-09-14 2007-03-22 Janssen Pharmaceutica, N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de kinase c-fms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096795A2 (fr) * 2003-04-25 2004-11-11 3-Dimensional Pharmaceuticals, Inc. Inhibiteurs de la kinase c-fms
US7642270B2 (en) * 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09221424A (ja) * 1995-12-13 1997-08-26 Dainippon Pharmaceut Co Ltd 抗腫瘍剤
WO2001070741A1 (fr) * 2000-03-06 2001-09-27 Warner-Lambert Company Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido[2,3-d]pyrimidines
WO2007033232A1 (fr) * 2005-09-14 2007-03-22 Janssen Pharmaceutica, N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de kinase c-fms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199747, Derwent World Patents Index; AN 1997-506304, XP002472582 *

Also Published As

Publication number Publication date
CL2007003163A1 (es) 2008-06-27
US20080114007A1 (en) 2008-05-15
AR063723A1 (es) 2009-02-11
WO2008055013A2 (fr) 2008-05-08

Similar Documents

Publication Publication Date Title
WO2008055013A3 (fr) 5-oxo-5,8-dihydro-pyrido-pyrimidines comme inhibiteurs de la kinase c-fms
LTC3106463I2 (lt) Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip trk kinazės slopikliai
WO2010151710A3 (fr) Composés hétérocycliques substitués utilisés en tant qu'inhibiteurs de la kinase et leur procédé d'utilisation
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2009016460A3 (fr) Composés pyrazoles
WO2010008847A3 (fr) Inhibiteurs de pi3k/m tor
WO2009079008A8 (fr) Benzopyranes et analogues utilisés comme inhibiteurs de la rho kinase
MX2009001067A (es) Formas cristalinas de analogos de rapamicina.
WO2008016192A3 (fr) Dérivé hétérocyclique fusionné et son procédé d'utilisation
WO2007023382A3 (fr) Composes de pyrimidine amino pyrazole, puissants inhibiteurs de kinase
WO2010014930A3 (fr) Agents thérapeutiques
WO2012107201A3 (fr) Exhausteurs de goût sucré, compositions édulcorantes, procédés permettant de les fabriquer et produits alimentaires les contenant
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
SI2021335T1 (sl) Heterocikliäśne spojine kot zaviralci c-fms kinaze
WO2008155615A3 (fr) Procédé perfectionné pour la préparation d'un antibiotique de la famille des céphalosporines
WO2006127815A3 (fr) Composes benzimidazole-carboxamide utilises comme agonistes du recepteur 5-ht4
WO2010001257A3 (fr) Nouvelles formes à l’état solide de laquinimod et son sel de sodium
WO2010144499A3 (fr) Dérivés d'urée comme inhibiteurs de kinase
WO2006138673A3 (fr) Procedes synthetiques de preparation de composes d'ether aminocyclohexyle
MX2012013332A (es) Preparacion de intermediarios de posaconazol.
MX2009010302A (es) Derivados de indol que tienen actividad inhibidora de cpla2 y aplicaciones y metodos de produccion.
WO2007000340A3 (fr) Derives bicycliques utilises en tant qu'inhibiteurs de kinase p38
WO2009154754A3 (fr) Synthèse de dérivés de morpholine deutérés
WO2009047499A3 (fr) Procédés de préparation de palipéridone et de ses sels pharmaceutiquement acceptables et d'intermédiaires pour une utilisation dans les procédés
WO2006066044A3 (fr) Procedes de production de 4-aminoquinazolines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07854231

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07854231

Country of ref document: EP

Kind code of ref document: A2